ROBERTET GROUP - INTERIM CONSOLIDATED FINANCIAL STATEMENTS - HALF-YEAR 2026
news
ROBERTET GROUP - INTERIM CONSOLIDATED FINANCIAL STATEMENTS - HALF-YEAR 2026
The Daily Recap
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.More to Read
news
Former Eversheds Sutherland CEO Mark Wasserman Joins FTI Consulting
Longtime law firm leader will help assemble multidisciplinary teams for law firms, corporate legal departments, boards and senior executives navigating high-stakes events WASHINGTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of former Eversheds Sutherland CEO Mark Wasserman as a Senior Managing Director focused on advising law firms, corporate legal departments, boards and senior executives. Mr. Wasserman, who is based in Atlanta, joins FT
news
Brutus Mining to Acquire the Bay of Islands Hydrogen Project
VANCOUVER, British Columbia, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Brutus Mining Inc. (“ Brutus ” or the “ Company ”) ( CSE: BRU ) ( FSE: ZI3 ) is pleased to announce it has entered into a Property Option Agreement dated November 5, 2026 (the “ Agreement ”) with Benton Resources Inc. (TSXV: BEX) and Metals Creek Resources Corp. (TSXV: MEK) (together, the “ Optionors ”) under which the Company has been granted the option to acquire a 100% interest in the Bay of Islands Project (the “ Project ”) in We
news
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data Immunomodulator-free durability data from the complete Phase 1/2 dermatomyositis cohort at one year and from the complete Phase 1/2 lupus nephritis cohort with follow-up as long as two years as well as updated safety data from the RESET™ program with preconditioning to be presente
news
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in new-onset Stage 3 T1D Operational runway through 2028 to support registrational clinical development and pre-commercial activities of SAB-142 for Stage 3 T1D Conference call today at 8:30 AM ET MIAMI, Nov. 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeuti
news
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3’26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON,
news
MACOM Reports Fiscal Fourth Quarter and Fiscal Year 2026 Financial Results
LOWELL, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal fourth quarter and fiscal year ended October 2, 2026. Fourth Quarter Fiscal Year 2026 GAAP Results Revenue was $424.8 million, an increase of 62.7%, compared to $261.2 million in the previous year fiscal fourth quarter and an increase of 24.1% compared to $342.2 million in the prior
news
Kelly Reports Third-Quarter 2026 Earnings
TROY, Mich., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kelly (Nasdaq: KELYA, KELYB), a leading specialty talent solutions provider, today announced results for the third quarter of 2026. Q3 revenue of $0.9 billion , down 0.8% year-over-year, an improvement of 500 basis points (“bps”) versus the prior quarter; underlying revenue, which excludes previously disclosed discrete impacts, grew 2.3% year-over-year ETM underlying revenue grew 7.7% ( 2.4% reported) while SET underlying revenue decreased 0.8% ( 2.
news
Cronos Group Reports 2026 Third Quarter Results
Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count Net revenue in Q3 20 26 increased by 73% year-over-year on an organic, constant-currency basis Generated record net revenue in Canada, with Spinach ® maintaining #1 market share in vapes and edibles 1 Eleventh consecutive quarter of record net revenue in Israel, where PEACE NATURALS ® remains the #1 cannabis brand 2 Delivered record net revenue in Germany TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE)
Comments (0)
Login to join the conversation
Login / RegisterNo comments yet. Be the first to comment!